Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_assertion type Assertion NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_head.
- NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_assertion description "[The data in this study of a large number of cancer patients receiving intravenous bisphosphonates suggest that MHC class II polymorphisms represent genetic risk factors for the development of ARONJ.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_provenance.
- NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_assertion evidence source_evidence_literature NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_provenance.
- NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_assertion SIO_000772 23218978 NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_provenance.
- NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_assertion wasDerivedFrom befree-2016 NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_provenance.
- NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_assertion wasGeneratedBy ECO_0000203 NP1033969.RAToTYM-0p56aU8eMFEzeFzA9fKv3fsfv4kl7D6a4Z8QU130_provenance.